Solid Biosciences Inc.
Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophi…
Biotechnology
US, Cambridge [HQ]
Document Reader
Link Index · Filing Reader · 10K/10QThis analysis tool lets you read the documents of Solid Biosciences Inc.
DEF 14-A Proxies
10-Ks
10-Qs
Not a single 10-Q doc.
LDA 1/2s
Click To Read:
DEF 14-A Proxies
Not a single DEF 14-A proxy doc.
10-K Filings
Not a single 10-K doc.
10-Q Filings
Not a single 10-Q doc.
LDA 1/2 Filings [Lobbying]
Not a single LDA doc.